Vir Biotechnology, Inc. Income Taxes Paid
Vir Biotechnology, Inc. (VIR) reported Income Taxes Paid of $2.42 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:IncomeTaxesPaidNet · last filed 2026-02-23
- Vir Biotechnology, Inc. income taxes paid, net for the quarter ending 2025-12-31 was $154.00K, a 80.41% decline year-over-year.
- Vir Biotechnology, Inc. income taxes paid, net for the quarter ending 2025-09-30 was $4.53M.
- Vir Biotechnology, Inc. income taxes paid, net for the quarter ending 2024-12-31 was $786.00K.
- Vir Biotechnology, Inc. income taxes paid, net for the quarter ending 2024-09-30 was $0.00.
- Vir Biotechnology, Inc. income taxes paid, net for fiscal 2025 was $2.42M, a 207.89% increase from fiscal 2024.
- Vir Biotechnology, Inc. income taxes paid, net for fiscal 2024 was $786.00K, a 70.63% decline from fiscal 2023.
- Vir Biotechnology, Inc. income taxes paid, net for fiscal 2023 was $2.68M.
- Vir Biotechnology, Inc. income taxes paid, net for fiscal 2022 was -$252.03M.
| Period end | Income Taxes Paid, Net 3 month | Income Taxes Paid, Net 6 month | Income Taxes Paid, Net 9 month | Income Taxes Paid, Net 12 month | Income Taxes Paid, Net 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $154.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $4.69M derived: sum of 2 quarters · filed 2026-02-23 | $2.42M 10-K · filed 2026-02-23 | ||
| 2025-09-30 | $4.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $2.27M 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | -$2.27M 10-Q · filed 2025-08-06 | ||||
| 2024-12-31 | $786.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $786.00K derived: sum of 2 quarters · filed 2025-11-05 | $786.00K 10-K · filed 2025-02-27 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-06 | ||||
| 2023-12-31 | $2.68M 10-K · filed 2025-02-27 | ||||
| 2022-12-31 | -$443.68M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$341.45M derived: sum of 2 quarters · filed 2025-02-27 | -$252.03M 10-K · filed 2025-02-27 | $252.03M 10-K · filed 2023-02-28 | |
| 2022-09-30 | $102.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $191.65M 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $89.42M 10-Q · filed 2022-08-09 | ||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $0.00 derived: sum of 2 quarters · filed 2024-02-26 | $0.00 10-K · filed 2024-02-26 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-09 | ||||
| 2020-12-31 | $0.00 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |